总部位于法国的赛诺菲今年2月宣布,它将加入生产疫苗的行列,并已获得美国卫生部门的支持。
GSK is already offering access to its technology to smaller teams, such as a vaccine effort at the University of Queensland, but this is the first collaboration that would have the ability to rapidly scale up manufacturing.
葛兰素史克已经在向规模较小的团队提供技术,比如澳大利亚昆士兰大学的疫苗项目,但与赛诺菲的合作是首次能够快速提升生产规模的合作。
Two companies joining forces, rather than competing, in a vaccine effort is extremely unusual, but the urgent need for a Covid-19 vaccine and the potential scale of the market is also not a typical situation.
两家公司在疫苗研发领域展开合作而不是竞争,这是极其罕见的。不过,对于新冠疫苗的迫切需求和市场的潜在规模也并不常见。
The vaccine is based on an existing DNA-based technology that Sanofi uses to make its flu vaccine.
两家公司合作研发的这种疫苗将基于赛诺菲用于生产流感疫苗的现有脱氧核糖核酸 When the coronavirus invades the body, immune cells fight back by producing antibodies. These antibodies bind to specific structures on the foreign invader, called the antigen. In the case of Covid-19 the antigen is a spike-like protein on its exterior.
当新冠病毒入侵人体时,免疫细胞通过产生抗体进行反击。这些抗体会与外来入侵者身上的特定结构结合在一起,这些特定结构被称为抗原。就新冠病毒而言,抗原是其表面的一种刺突状蛋白。
【英法制药巨头联手研发新冠疫苗 明年或大量上市】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15